TIKTOK
6.9.2018 12:57:28 CEST | Business Wire | Press release
TikTok, the go-to destination for the creating and viewing short-term mobile videos, has arrived in the global capital of fashion: Paris. The worldwide phenomenon held its first event on Tuesday September 4 during a unique night on the Seine. With its “80’s vs 2080 theme, TikTok took its community on a creative and innovative adventure, like its platform. The brand also welcomed today’s most creative influencers to celebrate the arrival of the new TikTok platform, born from the union with the Musical.ly app, and has thus unveiled application’s new innovative features and technological innovations of the application, such as "reaction" function that allows users to react directly to their friends' videos.
TikTok : a new groundbreaking upgrade
A global platform now
present in more than 150 countries and regions, TikTok was one of the
most downloaded applications in the world in early 20181
. The
latest update, which incorporates the best of both applications, has
allowed TikTok to creatively connect its community in a multicultural
environment. The newly upgraded platform, offers greater capabilities
for video creation and allows creators to enjoy the opportunity to reach
a bigger and more diverse global audience. By providing an intuitive,
creative and personalized visualization experience, TikTok enables its
community to create and discover tomorrow's trends
Chenyi Qiu, Director of TikTok Operations in West Europe, said: "The rebranding of TikTok in Europe marks a new milestone for us! Through this event we wish to celebrate the diversity of our platform and thus put creativity in the spotlight in different sectors. That is why we approach the theme of sustainable fashion with our community. "
TikTok inspires the best creators and influencers
For the
launch of the new TikTok platform in France, the application paid
tribute to the creativity of its community by organizing original
workshops. To make this moment a memorable evening, TikTok partnered
with the best, and invited creators from different horizons: fashion,
music, dance, makeup, ...
Claire Dartigues, fashion designer and finalist of the 2017 Redress Award, gave a workshop on the importance of sustainable fashion. Claire also inspired her audience by showing them how to create a unique and original outfit entirely made of recyclable materials. During another workshop, TikTok’s influencers and creators unveiled the breadth of their creativity and shared their best tips for creating innovative and creative videos.
Much more than just videos!
With the help of many
influencers including Youtuber Shera
Kerienski
and influencer Estelle
Fitz
, the app unveiled many of the application’s new features.
TikTok presented the "reaction" function
which allows
the user to react directly to their friends’ videos on their phone. This
innovative technology allows users to interact with videos by
integrating their reactions into the content they are viewing. The
platform also unveiled its new
interactive filters made possible by artificial intelligence
,
allowing users to apply filters to their entire body and trigger new
special effects. Rachel
Ward
, famous influencer from TikTok, said : "TikTok is a great app
because it gave me the courage to be myself and have fun the community
is supportive, friendly and diverse."
About TikTok
TikTok is a
destination for short-form mobile videos. Our mission is to capture and
present the world's creativity, knowledge, and moments that matter,
directly from the mobile phone. TikTok enables everyone to be a creator
and encourages users to share their passion and creative expression
through their videos. TikTok is based in Los Angeles, with global
offices in London, Tokyo, Seoul, Shanghai, Beijing, Singapore, Jakarta,
Mumbai, and Moscow. In early 2018, TikTok was one of the most downloaded
apps in the world. TikTok is available worldwide for iOS
and Android
. Visit tiktok.com
.
1 Sensor tower, 1Q report
View source version on businesswire.com: https://www.businesswire.com/news/home/20180906005390/en/
Contact:
Agence Burson Cohn&Wolfe Giulia Goodwin - Charlotte Durand tiktokfr@cohnwolfe.com +33 (0)1 56 03 13 83 / +33 (0)6 28 79 11 40 +33 1 56 03 13 66
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom